MENU
QURE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

QURE stock forecast, quote, news & analysis

uniQure NV is a gene therapy company... Show more

Industry: #Biotechnology
A.I.Advisor
published price charts
QURE
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for QURE with price predictions
Oct 21, 2026

QURE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 29, 2026

QURE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where QURE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Moving Average Convergence Divergence (MACD) for QURE just turned positive on October 16, 2026. Looking at past instances where QURE's MACD turned positive, the stock continued to rise in 29 of 40 cases over the following month. The odds of a continued upward trend are 73%.

Following a +4.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where QURE advanced for three days, in 206 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

QURE moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for QURE crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QURE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for QURE entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.857) is normal, around the industry mean (2.988). P/E Ratio (-5.589) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (142.857) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. QURE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QURE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 58 to 132.95B. VRTX holds the highest valuation in this group at 132.95B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -15%. SLN experienced the highest price growth at 119%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -21%. For the same stocks of the Industry, the average monthly volume growth was 5% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
QURE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company which engages in the discovery, development, and commercialization of gene therapies

Industry Biotechnology

Industry
Biotechnology
Address
Paasheuvelweg 25
Phone
+31 202406000
Employees
221
Web
https://www.uniqure.com
QURE in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 29, 2026